T1	Participants 50 81	patients with advanced melanoma
T2	Participants 620 671	single-agent TMZ in patients with advanced melanoma
T3	Participants 727 766	132 patients were enrolled on the study
T4	Participants 768 801	Patient and tumor characteristics
T5	Participants 843 876	Patients with cerebral metastases
T6	Participants 892 900	Patients
T7	Participants 1124 1141	16 patients (26%)
T8	Participants 1155 1172	19 patients (29%)
